NCT00121108 - MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States | Biotech Hunter

Enrollment

2,127

Participants

Timeline

Start Date

November 15, 2004

Primary Completion Date

December 27, 2010

Study Completion Date

December 27, 2010

Conditions

Healthy

Interventions

BIOLOGICAL

Motavizumab

Intramuscular dose of motavizumab 15 mg/kg will be administered every 30 Days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the RSV season.

OTHER

Placebo

Intramuscular dose of placebo matched to motavizumab will be administered every 30 days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the the RSV season.

Trial Locations (12)

21205

Research Site, Baltimore

Unknown

Research Site, Chinle

Research Site, Cibecue

Research Site, Fort Definace

Research Site, San Carlos

Research Site, Tuba City

Research Site, Whiteriver

Research Site, Winslow

Research Site, Bloomfield

Research Site, Crownpoint

Research Site, Gallup

Research Site, Shiprock